NO20063279L - Fremgangsmater og sammensetninger til behandling av lipodystrofi - Google Patents

Fremgangsmater og sammensetninger til behandling av lipodystrofi

Info

Publication number
NO20063279L
NO20063279L NO20063279A NO20063279A NO20063279L NO 20063279 L NO20063279 L NO 20063279L NO 20063279 A NO20063279 A NO 20063279A NO 20063279 A NO20063279 A NO 20063279A NO 20063279 L NO20063279 L NO 20063279L
Authority
NO
Norway
Prior art keywords
lipodystrophy
treatment
methods
compositions
hiv
Prior art date
Application number
NO20063279A
Other languages
English (en)
Norwegian (no)
Inventor
Giampiero De Luca
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of NO20063279L publication Critical patent/NO20063279L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20063279A 2004-01-29 2006-07-14 Fremgangsmater og sammensetninger til behandling av lipodystrofi NO20063279L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54020404P 2004-01-29 2004-01-29
US54336604P 2004-02-10 2004-02-10
PCT/EP2005/000758 WO2005074916A1 (en) 2004-01-29 2005-01-26 Methods and compositions for the treatment of lipodystrophy

Publications (1)

Publication Number Publication Date
NO20063279L true NO20063279L (no) 2006-09-19

Family

ID=34841102

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063279A NO20063279L (no) 2004-01-29 2006-07-14 Fremgangsmater og sammensetninger til behandling av lipodystrofi

Country Status (10)

Country Link
EP (1) EP1722778A1 (ko)
JP (1) JP2007519669A (ko)
KR (1) KR20060127977A (ko)
AU (1) AU2005210093A1 (ko)
BR (1) BRPI0507302A (ko)
CA (1) CA2552404A1 (ko)
EA (1) EA200601392A1 (ko)
IL (1) IL176762A0 (ko)
NO (1) NO20063279L (ko)
WO (1) WO2005074916A1 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2903312B1 (fr) 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
JP5570999B2 (ja) * 2008-01-03 2014-08-13 ユニベルシテ デ―マルセイユ 抗hiv治療の際に使用される組成物
WO2010121352A1 (en) * 2009-04-20 2010-10-28 Theratechnologies Inc. Use of (hexenoyl trans-3)hgrf(l-44)nh2 and simvastatin in combination therapy
EP3125921B1 (en) * 2014-03-11 2020-07-08 Novartis AG Fgf21 variants for use in treating hiv-haart induced partial lipodystrophy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9803623D0 (sv) * 1998-10-22 1998-10-22 Sahltech Ab New therapeutic application

Also Published As

Publication number Publication date
KR20060127977A (ko) 2006-12-13
WO2005074916A1 (en) 2005-08-18
EA200601392A1 (ru) 2006-12-29
IL176762A0 (en) 2006-10-31
BRPI0507302A (pt) 2007-06-26
JP2007519669A (ja) 2007-07-19
EP1722778A1 (en) 2006-11-22
AU2005210093A1 (en) 2005-08-18
CA2552404A1 (en) 2005-08-18

Similar Documents

Publication Publication Date Title
WO2006068729A3 (en) Methods and compositions for enhancing iron absorption
WO2008030505A8 (en) Methods and compositions for the treatment of antibody mediated neuropathies
WO2009115652A3 (fr) Bi- et tri-therapie utilisables lors du traitement d' un patient infecte par le vih
WO2009044173A3 (en) Methods of treating cancer using notch pathway inhibitors
MX2009013349A (es) Compuestos quimicos.
MX2009004038A (es) Gel de diclofenaco.
MX2007003095A (es) Metodos y dispositivos para cerrar los vasos sanguineos inducidos electricamente no termicos.
WO2007120626A3 (en) Uses and compositions for treatment of ankylosing spondylitis
ATE499109T1 (de) Zusammensetzung zur proteasomhemmung
WO2005117870A3 (en) Combination of proton pump inhibitor, buffering agent, and prokinetic agent
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
NO20075304L (no) Metode for avtagende forkalkning
EP1670450B8 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
NO20054371L (no) Somatostatin-dopamin kimaere analoger
TW200716224A (en) Method of indentifying therapeutic targets for the treatment of vulvovaginal atrophy
MX350046B (es) Tratamientos para trastornos gastrointestinales.
WO2008118849A3 (en) Hiv-1 protease inhibitors
ATE541848T1 (de) Diaryl-purin, azapurine und deazapurine als nichtnukleoside reverse-transkriptase-inhibitoren zur behandlung von hiv
MX2022001004A (es) Inhibidores de enzimas.
TW200716088A (en) Formulations and methods for treating amyloidosis
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
NO20075764L (no) Kombinert anvendelse av prostaglandinforbindelse og protonpumpeinhibitor til behandling av forstyrrelser i mage- og tarmkanalen
NO20063279L (no) Fremgangsmater og sammensetninger til behandling av lipodystrofi
MX2009011930A (es) Terapia de combinacion para el tratamiento de infeccion de virus de hepatitis c.

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS

FC2A Withdrawal, rejection or dismissal of laid open patent application